Michele Merli

47PUBLICATIONS
190CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursPredictive and prognostic markersCardiology (incl. cardiovascular diseases)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (47)

|Sep 16, 2026
Real-World Determinants of Treatment Selection in Frontline Chronic Lymphocytic Leukemia: The FIRST-CLL Study.

|Sep 04, 2026
Role of direct-acting antivirals in people with HIV-associated non-Hodgkin lymphoma and concomitant HCV infection: A study on behalf of the Fondazione Italiana Linfomi.

|Aug 31, 2026
Survival after first relapse in marginal zone lymphomas: Prospective data from the international observational NF10 study.

|Nov 10, 2025
Clinical Presentation, Treatment, and Outcomes of 28 Patients With Castleman Disease: A Retrospective Analysis of an Italian Cohort.

Caterina Cristinelli, Michele Merli, Marco Lucioni

|Nov 28, 2024
Efficacy and safety of bendamustine, rituximab and bortezomib treatment in relapsed/refractory Waldenstrom Macroglobulinaemia: results of phase 2 single-arm FIL-BRB trial.

Giulia Benevolo, Daniela Drandi, Nicoletta Villivà

|Jul 23, 2024
Exposure to obinutuzumab does not affect outcomes of SARS-CoV-2 infection in vaccinated patients with newly diagnosed advanced-stage follicular lymphoma.

A Pinto, M Caltagirone, M Battista

Pageof 8

Frequent Collaborators

18 joint publications

Luca Arcaini

13 joint publications

Francesco Passamonti

7 joint publications

Emanuele Cencini

7 joint publications

Marzia Varettoni